Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk

Michael Gertz,Nikolaos Tsamandouras,Carolina Säll,J. Brian Houston,Aleksandra Galetin

Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk

2014

Michael Gertz
Nikolaos Tsamandouras
Carolina Säll
J. Brian Houston
Aleksandra Galetin

Purpose To investigate the effect of OATP1B1 genotype as a covariate on repaglinide pharmacokinetics and drug-drug interaction (DDIs) risk using a reduced physiologically-based pharmacokinetic (PBPK) model.

Keywords:

Covariate
Physiologically based pharmacokinetic modelling
CYP2C8
Drug-drug interaction
In vitro
Genotype
Pharmacology
Repaglinide
Pharmacokinetics
Chemistry

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations